- Home
- FGB vs MAIA Comparison
FGB vs MAIA Comparison
Compare FGB & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGB
- MAIA
- Stock Information
- Founded
- FGB 2007
- MAIA 2018
- Country
- FGB United States
- MAIA United States
- Employees
- FGB N/A
- MAIA N/A
- Industry
- FGB Finance/Investors Services
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- FGB Finance
- MAIA Health Care
- Exchange
- FGB Nasdaq
- MAIA Nasdaq
- Market Cap
- FGB 57.5M
- MAIA 46.7M
- IPO Year
- FGB N/A
- MAIA 2022
- Fundamental
- Price
- FGB $4.11
- MAIA $1.79
- Analyst Decision
- FGB
- MAIA
- Analyst Count
- FGB 0
- MAIA 0
- Target Price
- FGB N/A
- MAIA N/A
- AVG Volume (30 Days)
- FGB 53.0K
- MAIA 402.9K
- Earning Date
- FGB 01-01-0001
- MAIA 08-08-2025
- Dividend Yield
- FGB 8.92%
- MAIA N/A
- EPS Growth
- FGB N/A
- MAIA N/A
- EPS
- FGB N/A
- MAIA N/A
- Revenue
- FGB N/A
- MAIA N/A
- Revenue This Year
- FGB N/A
- MAIA N/A
- Revenue Next Year
- FGB N/A
- MAIA N/A
- P/E Ratio
- FGB N/A
- MAIA N/A
- Revenue Growth
- FGB N/A
- MAIA N/A
- 52 Week Low
- FGB $2.85
- MAIA $1.40
- 52 Week High
- FGB $3.74
- MAIA $4.24
- Technical
- Relative Strength Index (RSI)
- FGB 55.64
- MAIA 47.69
- Support Level
- FGB $3.98
- MAIA $1.66
- Resistance Level
- FGB $4.17
- MAIA $1.95
- Average True Range (ATR)
- FGB 0.06
- MAIA 0.10
- MACD
- FGB -0.00
- MAIA -0.00
- Stochastic Oscillator
- FGB 50.00
- MAIA 23.28
About FGB First Trust Specialty Finance and Financial Opportunities Fund
First Trust Specialty Fnc & Fncl Oppor is a United States-based closed-end management investment company. The Fund's primary investment objective is to seek a high level of current income. It seeks a positive total return as a secondary objective. The Fund seeks to achieve its investment objectives by investing at least 80% of its Managed Assets in a portfolio of securities of specialty finance and other financial companies.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.